Search

everythinglearnresearchcommunity

for

Search:↓

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

A 31-year-old experienced significant hair regrowth using Minoxidil 5% topical twice daily and Finasteride 0.625mg daily, with additional microneedling. The user reported initial shedding, improved hair thickness, and no major side effects, impressing their dermatologist with the results.

A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.

A 30-year-old with diffuse thinning and a balding crown is using a treatment regimen of a 2-in-1 pill containing finasteride, minoxidil, and biotin, along with various supplements. After two weeks, no side effects have been experienced, and updates with pictures will be posted monthly.

A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

A 31-year-old male shared his 4.5-month progress using finasteride, topical minoxidil, and dutasteride mesotherapy for hair loss, showing significant improvement in crown density and overall hair texture. He reported no side effects and plans to continue the treatment to assess further results.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A user reported significant hair regrowth after 3 months using 1mg oral finasteride, 1ml 5% topical minoxidil, and microneedling, along with biotin, vitamin D, iron, and zinc supplements. They are optimistic about continued progress despite initial skepticism.

A 31-year-old Indian man shared his 6-month hair loss progress using oral finasteride and topical minoxidil, showing noticeable improvement. Replies were positive, noting thicker hair and a better hairline.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

A 36-year-old man shared his 1.25-year progress using oral finasteride, oral minoxidil, RU58841, microneedling, nizoral, and LLLT for hair regrowth. He is thrilled with the results and considering a hair transplant for increased density.

A user's successful hair regrowth over 33 months using daily finasteride and minoxidil, microneedling 2-4 times per month, and maintaining a healthy lifestyle. The user's progress has inspired others to consider similar treatments for hair loss.

The user experienced significant hair regrowth using topical Minoxidil and Finasteride but had to stop due to high liver enzyme levels. They plan to pause treatment for a month to see if their liver values return to normal.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A 31-year-old has been using 1mg finasteride, 5mg minoxidil, minoxidil spray, a dermaroller, and Nizoral shampoo for hair regrowth. The treatments have resulted in thick, healthy hair, and the user has been on finasteride since 2022, switching from lotion to pills in 2025.